Note 2 - Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2026 |
|---|
| Notes Tables |
|
| Segment Reporting [Table Text Block] |
| | For the Three Months Ended September 30, | | | For the Nine Months Ended September 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Cost of sales | | $ | 15,198 | | | $ | 12,173 | | | | 38,097 | | | $ | 35,030 | |
General and administrative | | | 5,217 | | | | 6,142 | | | | 16,706 | | | | 18,860 | |
Commercialization | | | 9,795 | | | | 9,623 | | | | 31,957 | | | | 30,330 | |
Research and development: | | | | | | | | | | | | | | | | |
Clinical research and development | | | 9,341 | | | | 7,789 | | | | 31,449 | | | | 21,881 | |
Medical affairs | | | 1,203 | | | | 1,323 | | | | 3,683 | | | | 4,107 | |
Other research and development (1) | | | 7,007 | | | | 6,179 | | | | 19,579 | | | | 17,190 | |
Operating costs and expenses | | | 47,761 | | | | 43,229 | | | | 141,471 | | | | 127,398 | |
Stock-based compensation | | | 2,021 | | | | 1,673 | | | | 5,870 | | | | 5,327 | |
Total operating costs and expenses | | $ | 49,782 | | | $ | 44,902 | | | $ | 147,341 | | | $ | 132,725 | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
| | For the Three Months Ended | | | For the Nine Months Ended | |
| | September 30, | | | September 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Options outstanding | | | 1,714,761 | | | | 2,947,276 | | | | 1,819,455 | | | | 3,718,413 | |
Warrant outstanding | | | 2,116,250 | | | | 2,116,250 | | | | 2,116,250 | | | | 2,116,250 | |
Unvested restricted stock units | | | 10,940 | | | | 229,495 | | | | 14,344 | | | | 354,821 | |
Totals | | | 3,841,951 | | | | 5,293,021 | | | | 3,950,049 | | | | 6,189,484 | |
|
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
| | For the Three Months Ended September 30, | | | For the Nine Months Ended September 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Numerator: | | | | | | | | | | | | | | | | |
Net income | | $ | 5,956 | | | $ | 8,844 | | | $ | 10,392 | | | $ | 17,673 | |
Denominator: | | | | | | | | | | | | | | | | |
Weighted average common stock outstanding for basic net income per share | | | 51,602,295 | | | | 50,339,456 | | | | 51,131,897 | | | | 49,881,181 | |
Net effect of dilutive common stock equivalents | | | 1,514,541 | | | | 590,437 | | | | 1,473,117 | | | | 453,372 | |
Weighted average common stock outstanding for diluted net income per share | | | 53,116,836 | | | | 50,929,893 | | | | 52,605,014 | | | | 50,334,553 | |
Net income per share of common stock | | | | | | | | | | | | | | | | |
Basic | | $ | 0.12 | | | $ | 0.18 | | | $ | 0.20 | | | $ | 0.35 | |
Diluted | | $ | 0.11 | | | $ | 0.17 | | | $ | 0.20 | | | $ | 0.35 | |
|
| Fair Value, Assets Measured on Recurring Basis [Table Text Block] |
September 30, 2026 | | Level 1 | | | Level 2 | | | Level 3 | | | Total | |
Cash Equivalents | | $ | 12,350 | | | $ | 21,086 | | | $ | — | | | $ | 33,436 | |
U.S. Government Securities | | | 28,349 | | | | 7,113 | | | | — | | | | 35,462 | |
Corporate Bonds | | | — | | | | 6,229 | | | | — | | | | 6,229 | |
Commercial Paper | | | — | | | | 25,336 | | | | — | | | | 25,336 | |
Totals | | $ | 40,699 | | | $ | 59,764 | | | $ | — | | | $ | 100,463 | |
December 31, 2025 | | Level 1 | | | Level 2 | | | Level 3 | | | Total | |
Cash Equivalents | | $ | 5,060 | | | $ | 18,710 | | | $ | — | | | $ | 23,770 | |
U.S. Government Securities | | | 27,903 | | | | 14,873 | | | | — | | | | 42,776 | |
Corporate Bonds | | | — | | | | 6,865 | | | | — | | | | 6,865 | |
Commercial Paper | | | — | | | | 18,252 | | | | — | | | | 18,252 | |
Totals | | $ | 32,963 | | | $ | 58,700 | | | $ | — | | | $ | 91,663 | |
|
| Cash, Cash Equivalent, and Investment [Table Text Block] |
| Maturity | | Amortized | | | Unrealized | | | Estimated | |
September 30, 2026 | (in years) | | Cost | | | Gains | | | Losses | | | Fair Value | |
Cash Equivalents | | $ | 33,436 | | | $ | — | | | $ | — | | | $ | 33,436 | |
U.S. Government Securities | Less than 1 | | | 35,525 | | | | — | | | | (63 | ) | | | 35,462 | |
Corporate Bonds | Less than 1 | | | 6,239 | | | | — | | | | (10 | ) | | | 6,229 | |
Commercial Paper | Less than 1 | | | 25,361 | | | | — | | | | (25 | ) | | | 25,336 | |
Totals | | $ | 100,561 | | | $ | — | | | $ | (98 | ) | | $ | 100,463 | |
| Maturity | | Amortized | | | Unrealized | | | Estimated | |
December 31, 2025 | (in years) | | Cost | | | Gains | | | Losses | | | Fair Value | |
Cash Equivalents | | $ | 23,772 | | | $ | — | | | $ | (2 | ) | | $ | 23,770 | |
U.S. Government Securities | Less than 1 | | | 42,739 | | | | 37 | | | | — | | | | 42,776 | |
Corporate Bonds | Less than 1 | | | 6,866 | | | | 1 | | | | (2 | ) | | | 6,865 | |
Commercial Paper | Less than 1 | | | 18,250 | | | | 3 | | | | (1 | ) | | | 18,252 | |
Totals | | $ | 91,627 | | | $ | 41 | | | $ | (5 | ) | | $ | 91,663 | |
|
| Schedule of Inventory, Current [Table Text Block] |
| | September 30, 2026 | | | December 31, 2025 | |
Raw materials | | $ | 7,278 | | | $ | 3,212 | |
Work-in-process | | | 3,344 | | | | 1,343 | |
Finished goods | | | 869 | | | | 960 | |
Total inventories | | $ | 11,491 | | | $ | 5,515 | |
|